High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Daien, Claire I ^a,b,c   Gailhac, Sarah ^b   Mura, Thibault ^d   Combe, Bernard ^a,c   Hahne, Michael ^b,c,e   Morel, Jacques ^a,b,c  

^a LAPEYRONIE HOSPITAL   (France)

^b CNRS   (France)

^c UNIV MONTPELLIER   (France)

^d HÔPITAL SAINT ELOI   (France)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CD19 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EDETIC ACID; ETANERCEPT; IMMUNOGLOBULIN D; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR ALPHA; GAMMA INTERFERON; GLUCOCORTICOID;

ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DAS28; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; OSTEOARTHRITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PREDICTIVE VALUE; PROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TH1 CELL; ADULT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME; CELLULAR DISTRIBUTION; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; BIOLOGICAL MARKERS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901696212     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4543     Document Type: Article

References (21)

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F, National Arthritis Data Workgroup Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis Rheum 2008, 58:26-35. 10.1002/art.23176, 3266664, 18163497, National Arthritis Data Workgroup.
2. Müller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 2005, 1:102-110. 10.1038/ncprheum0047, 16932639.
3. Tracey KJ, Cerami A. Tumor necrosis factor: an updated review of its biology. Crit Care Med 1993, 21:S415-S422.
4. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, Fleisher TA, Wilson M, Goldbach-Mansky R, Lipsky PE. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther 2009, 11:R84. 10.1186/ar2718, 2714135, 19500335.
5. Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner ECB, Miller CH, Dutcher PO, Hadley JA, Sanz I. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008, 180:688-692. 10.4049/jimmunol.180.2.688, 18178805.
6. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, Holers VM. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006, 116:961-973. 10.1172/JCI25422, 1421345, 16585962.
7. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001, 167:4710-4718. 10.4049/jimmunol.167.8.4710, 11591802.
8. Marston B, Palanichamy A, Anolik JH. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol 2010, 22:307-315. 10.1097/BOR.0b013e3283369cb8, 2947313, 20090526.
9. Roll P, Muhammad K, Schumann M, Kleinert S, Tony HP. RF positivity has substantial influence on the peripheral memory B-cell compartment and its modulation by TNF inhibition. Scand J Rheumatol 2012, 41:180-185. 10.3109/03009742.2011.645056, 22400711.
10. van der Linden MPM, Knevel R, Huizinga TWJ, van der Helm-van Mil AHM. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum 2011, 63:37-42. 10.1002/art.30100, 20967854.
11. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998, 41:1845-1850. 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K, 9778226.
12. Zhao J, Zhao J, Perlman S. Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-γ, IL-2 and IL-2R. PLoS One 2012, 7:e46241. 10.1371/journal.pone.0046241, 3459844, 23029447.
13. de la Torre I, Moura RA, Leandro MJ, Edwards J, Cambridge G. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy. Ann Rheum Dis 2010, 69:2181-2188. 10.1136/ard.2010.131326, 20581016.
14. Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loët X, Combe B, Dougados M, Mariette X, Taoufik Y. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2011, 63:3692-3701. 10.1002/art.30599, 22127692.
15. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, Lee EH, Milner ECB, Sanz I. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007, 178:6624-6633. 10.4049/jimmunol.178.10.6624, 17475894.
16. Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, Radbruch A, Hansen A, Burmester GR, Diamond B, Lipsky PE, Dörner T. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008, 58:1762-1773. 10.1002/art.23498, 18512812.
17. Michelutti A, Gremese E, Morassi F, Petricca L, Arena V, Tolusso B, Alivernini S, Peluso G, Bosello SL, Ferraccioli G. B-cell subsets in the joint compartments of seropositive and seronegative rheumatoid arthritis (RA) and no-RA arthritides express memory markers and ZAP70 and characterize the aggregate pattern irrespectively of the autoantibody status. Mol Med 2011, 17:901-909. 3188870, 21607290.
18. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation?. J Immunol 2004, 172:3422-3427. 10.4049/jimmunol.172.6.3422, 15004141.
19. Boussiotis VA, Nadler LM, Strominger JL, Goldfeld AE. Tumor necrosis factor α is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci U S A 1994, 91:7007-7011. 10.1073/pnas.91.15.7007, 44327, 7518925.
20. Menard LC, Minns LA, Darche S, Mielcarz DW, Foureau DM, Roos D, Dzierszinski F, Kasper LH, Buzoni-Gatel D. B cells amplify IFN-γ production by T cells via a TNF-α-mediated mechanism. J Immunol 2007, 179:4857-4866. 10.4049/jimmunol.179.7.4857, 17878385.
21. Roll P, Dörner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008, 58:1566-1575. 10.1002/art.23473, 18512772.